ALDH1A1 and neoplasm: Additionally, xenograft tumors derived from trastuzumab-sensitive BT474 cells pretreated in vitro with DSF/Cu exhibited a significant decrease of tumor growth associated with the downregulation of p95HER2 and ALDH1A1 protein content compared to untreated tumors [48].